|
|
|
Volumn 29, Issue 2, 2008, Pages 192-200
|
|
Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
|
|
Author keywords
Allodynia; Analgesia; Cannabinoids; Cannabis; Causalgia; CBD; Fibromyalgia; Headache; Irritable bowel syndrome; Medical marijuana; Migraine; THC
|
|
Indexed keywords
2 ARACHIDONOYLGLYCEROL;
2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE;
ACETYLSALICYLIC ACID;
ANANDAMIDE;
ANTIDEPRESSANT AGENT;
CALCITONIN GENE RELATED PEPTIDE;
CANNABIDIOL;
CANNABINOID;
CANNABINOID 1 RECEPTOR;
CANNABINOID 1 RECEPTOR AGONIST;
CANNABINOID 1 RECEPTOR ANTAGONIST;
CANNABIS;
DOPAMINE;
DRONABINOL;
ENDOCANNABINOID;
HYDROCORTISONE;
KETAMINE;
MORPHINE;
N METHYL DEXTRO ASPARTIC ACID;
N METHYL DEXTRO ASPARTIC ACID RECEPTOR;
NARCOTIC ANALGESIC AGENT;
PHENOBARBITAL;
PHENYTOIN;
RIMONABANT;
SEROTONIN 1A RECEPTOR;
SEROTONIN 2A ANTAGONIST;
SEROTONIN 2A RECEPTOR;
SUBSTANCE P;
UNINDEXED DRUG;
VIRODHAMINE;
ANTIINFLAMMATORY ACTIVITY;
BIPOLAR DISORDER;
CEREBROSPINAL FLUID EXAMINATION;
CLINICAL ENDOCANNABINOID DEFICIENCY;
COMORBIDITY;
DATA BASE;
DISEASE RESISTANCE;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG MEGADOSE;
FIBROMYALGIA;
GRAY MATTER;
HEADACHE;
HUMAN;
HYPERALGESIA;
IRRITABLE COLON;
MIGRAINE;
NEUROENDOCRINE DISEASE;
NEUROIMAGING;
NEUROTRANSMISSION;
NONHUMAN;
PAIN;
PATHOPHYSIOLOGY;
PHARMACOLOGICAL BLOCKING;
REVIEW;
SEIZURE;
|
|
EID: 43349090810
PISSN: 0172780X
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (62)
|
|
References (120)
|
